myTomorrows, an Amsterdam, The Netherlands-based provider of a drug access platform, raised €10m in growth funding.
The round was co-led by EQT Ventures and Octopus Ventures, with participation from existing investors Balderton Capital and Sofinnova Partners. In conjunction with the funding, former GlaxoSmithKline Chief Medical Officer James Shannon has also been appointed Chairman of the supervisory board.
The company will use the funds to further accelerate investments in technologies and talent.
Led by Founder CEO Ronald Brus, MD, myTomorrows provides a platform for doctors and patients seeking information on and access to investigational drugs, and drugs that have been approved by regulators in other countries. The company also offers drug developers a solution for global early access programs to make their drugs accessible to those suffering from life threatening or debilitating diseases whilst gathering data.
It is currently active in 17 countries.